[1] Adali M K B,Oguz K,Anil T,Yilmaz S T .2022 .Ticagrelor improves systemic immune-inflammation index in acute coronary syndrome patients. Acta Cardiol., 77(7) : 632-638.
[2] Akkaif M A,Ng M L,Sk Abdul Kader M A,Daud N A A,Sha' A,Ibrahim B .2021 .A review of the effects of ticagrelor on adenosine concentration and its clinical significance. Pharmacol. Rep, 73(6) : 1551-1564.
[3] Aleman MN,Luciardi MC,Albornoz ER,Bazán MC,Abregú AV MC .2024 .Relationship between inflammatory biomarkers and insulin resistance in excess-weight Latin children. Clin Exp Pediatr, 67(1) : 37-45.
[4] Angiolillo DJ,Galli M,Collet JP,Kastrati A,O'Donoghue ML .2022 .Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention, 17(17) : e1371-e1396.
[5] Bergmark BA,Mathenge N,Merlini PA,LawrenceWright MB,Giugliano RP .2022 .Acute coronary syndromes. The Lancet, 399(10332) : 1347-1358.
[6] Bhatt DL,Lopes RD,Harrington RA .2022 .Diagnosis and treatment of acute coronary syndromes: A review. JAMA, 327(7) : 662-675.
[7] Chen Y,Hsing S,Chao Y,Cheng Y,Lin C,Lin C,Fang W C .2022 .Clinical relevance of the LVEDD and LVESD trajectories in HF patients with LVEF <35%. , 9 : 1-14.
[8] Chyrchel B,Drożdż A,Długosz D,Stępień E,Surdacki A .2019 .Platelet reactivity and circulating platelet-derived microvesicles are differently affected by P2Y(12) receptor antagonists. Int J Med Sci., 16(2) : 264-275.
[9] Ciumărnean L,Milaciu MV,Negrean V,Orășan OH,Vesa SC,Sălăgean O,Iluţ S,Vlaicu SI .2022 .Cardiovascular risk factors and physical activity for the prevention of cardiovascular diseases in the elderly. Int. J. Environ. Res. Public Health, 19(1) : 207.
[10] Damluji A A,Forman D E,Wang T Y,Chikwe J,Kunadian V,Rich M W,Young B A,Page R L A,Alexander K P,Stroke C,Council on Cardiovascular N,Cardiometabolic H R .2023 .Management of acute coronary syndrome in the older adult population: A scientific statement from the american heart association. Circulation, 147(3) : e32-e62.
[11] Djuric M and Nenadic I,Djuric & D K Agrawal (Eds M .2024 .Environmental factors in the pathogenesis of cardiovascular diseases. , : 295-326.
[12] Hoole SP,Bambrough P .2020 .Recent advances in percutaneous coronary intervention. Heart, 106(18) : 1380-1386.
[13] Jiang L,Ji J,Ge P,Zhu T,Mi Q,Tai T,Li Y,Xie H Y .2022 .Is platelet responsiveness to clopidogrel attenuated in overweight or obese patients and why? A reverse translational study in mice. Br. J. Pharmacol., 179(1) : 46-64.
[14] Khalil J,Dimofte T,Roberts T,Keith M,Amaradasa K,Hindle MS,Bancroft S,Hutchinson JL,Naseem K,Johnson T,Mundell SJ .2024 .Ticagrelor inverse agonist activity at the P2Y12 receptor is non-reversible versus its endogenous agonist adenosine 5´- diphosphate. , 181(1) : 21-35.
[15] Kuszynski DS,Lauver DA .2022 .Pleiotropic effects of clopidogrel. , 18(3) : 253-265.
[16] Mahmoud I,Maryam A-K,,Ava A,Evan S,Gabriel S,Jill I,Nora RO,Heather O D,Linda G,Zoe F,Alan Mariño del P,Yvonne C,Adams BD C .2025 .The miRNA-9 isoform story in cancer: An oncomiR or tumor suppressor? J Can Biomol Therap. , 2(2) : 13-36.
[17] Maria P,Jessica H,Koen P,Barney CR,Daniel L,Yoon K L,Andrew M,Kalaivani M,Thomas WJ M .2022 .Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a "target trial". Open Heart, 9(2) : e001999.
[18] Maron David J,Hochman Judith S,Reynolds Harmony R,Bangalore S,O'Brien Sean M,Boden William E,Chaitman Bernard R,Senior R,López-Sendón J,Alexander Karen P,Lopes Renato D,Shaw Leslee J,Berger Jeffrey S,Newman Jonathan D,Sidhu Mandeep S,Goodman Shaun G,Ruzyllo W,Gosselin G,Maggioni Aldo P,White Harvey D,Bhargava B,Min James K,Mancini GBJ,Picard Michael H,Kwong Raymond Y,Ali Ziad A,Mark Daniel B,Spertus John A,Krishnan Mangalath N,Elghamaz A,Moorthy N,Hueb Whady A,Demkow M,Mavromatis K,Bockeria O,Peteiro J,Miller Todd D,Szwed H,Doerr R,Keltai M,Selvanayagam Joseph B,Steg P G,Held C,Kohsaka S,Mavromichalis S,Kirby R,Jeffries Neal O,Harrell Frank E,Rockhold Frank W,Broderick S,Ferguson TB,Williams David O,Harrington Robert A,Stone Gregg W,Rosenberg Y .2020 .Initial Invasive or Conservative Strategy for Stable Coronary Disease. N. Engl. J. Med, 382(15) : 1395-1407.
[19] Nakamura M,Yaku H,Ako J,Arai H,Asai T,Chikamori T,Daida H,Doi K,Fukui T,Ito T,Kadota K,Kobayashi J,Komiya T,Kozuma K,Nakagawa Y,Nakao K,Niinami H,Ohno T,Ozaki Y,Sata M,Takanashi S,Takemura H,Ueno T,Yasuda S,Yokoyama H,Fujita T,Kasai T,Kohsaka S,Kubo T,Manabe S,Matsumoto N,Miyagawa S,Mizuno T,Motomura N,Numata S,Nakajima H,Oda H,Otake H,Otsuka F,Shimada K,Shimokawa T,Shinke T,Suzuki T,Takahashi M,Tanaka N,Tsuneyoshi H,Tojo T,Une D,Wakasa S,Yamaguchi K,Akasaka T,Hirayama A,Kimura K,Kimura T,Matsui Y,Miyazaki S,Okamura Y,Ono M,Shiomi H,Tanemoto K .2022 .JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease. and on behalf of the Japanese Circulation Society, 86(3) : 477-588.
[20] Oikonomou E,Leopoulou M,Theofilis P,Antonopoulos A S,Siasos G,Latsios G,Mystakidi V C,Antoniades C,Tousoulis D C .2020 .A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases: Clinical and therapeutic implications. , 309 : 16-26.
[21] Ozaki Y,Tobe A,Onuma Y,Kobayashi Y,Amano T,Muramatsu T,Ishii H,Yamaji K,Kohsaka S,Ismail T F,Uemura S,Hikichi Y,Tsujita K,Ako J,Morino Y,Maekawa Y,Shinke T,Shite J,Igarashi Y,Nakagawa Y,Shiode N,Okamura A,Ogawa T,Shibata Y,Tsuji T,Hayashida K,Yajima J,Sugano T,Okura H,Okayama H,Kawaguchi K,Zen K,Takahashi S,Tamura T,Nakazato K,Yamaguchi J,Iida O,Ozaki R,Yoshimachi F,Ishihara M,Murohara T,Ueno T,Yokoi H,Nakamura M,Ikari Y,Serruys P W K .2024 .CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS. , 39(4) : 335-375.
[22] Rafique M,Solberg OG,Gullestad L,Bendz B,Murbraech K,Nytrøen K,Rolid K,Lunde K K .2023 .Effects of high-intensity interval training on cardiac remodelling, function and coronary microcirculation in de novo heart transplant patients: A substudy of the HITTS randomised controlled trial. BMJ Open Sport Exerc Med, 9(3) : e001331.
[23] Ren J .2024 .Advances in combination therapy for gastric cancer: Integrating targeted agents and immunotherapy. Adv Clin Pharmacol Ther, 1(1) : 1-15.
[24] Sahir F,Mateo J M M,Siveen K S .2024 .Development of a 43 color panel for the characterization of conventional and unconventional Tcell subsets, B cells, NK cells, monocytes, dendritic cells, and innate lymphoid cells using spectral flow cytometry. Cytometry A, 105(5) : 404-410.
[25] Shou Y,Li X,Fang Q,Xie A,Zhang Y,Fu X,Wang M,Gong W,Zhang X,Yang D .2024 .Progress in the treatment of diabetic cardiomyopathy, a systematic review. Pharmacol Res Perspect, 12(2) : e1177.
[26] Tamakauskas V,Žaliūnas R,Lesauskaitė V,Kupstytė- Krištaponė N,Šakalytė G,Jurgaitytė J,Čiapienė I,Tatarūnas V. .2022 .Factors determining ticagrelorinduced dyspnea in patients with acute coronary syndrome. Appl Sci, 12(19) : 10021.
[27] Tong J,Wang Z,Zhang J,Gao R,Liu X,Liao Y,Guo X,Wei Y .2024 .Advanced applications of nanomaterials in atherosclerosis diagnosis and treatment: Challenges and future prospects. ACS Appl Mater Interfaces, 16(43) : 58072-58099.
[28] Tsoupras A,Zabetakis I,Lordan R .2019 .Platelet aggregometry assay for evaluating the effects of platelet agonists and antiplatelet compounds on platelet function in vitro. Methods X, 6 : 63-70.
[29] Wang H,Liu Z,Shao J,Jiang M,Lu X,Lin L,Wang L,Xu Q,Zhang H,Li X,Zhou J,Chen Y,Zhang R Y .2022 .Pathogenesis of premature coronary artery disease: Focus on risk factors and genetic variants. Genes Dis., 9(2) : 370-380.
[30] Wang L,Wang J,Xu J,Qin W,Wang Y,Luo S,Wang G .2021 .The role and molecular mechanism of P2Y12 receptors in the pathogenesis of atherosclerotic cardiovascular diseases. Appl Sci, 11(19) : 78.
[31] Wang Y,Chen W,Lin Y,Meng X,Chen G,Wang Z,Wu J,Wang D,Li J,Cao Y,Xu Y,Zhang G,Li X,Pan Y,Li H,Zhao X,Liu L,Lin J,Dong K,Jing J,Johnston S C,Wang D,Wang Y .2019 .Ticagrelor plus aspirin versus clopidogrel plus aspirin for platelet reactivity in patients with minor stroke or transient ischaemic attack: open label, blinded endpoint, randomised controlled phase II trial. , 365 : l2211.
[32] Wei P,Wang X,Fu Q,Cao B .2024 .Progress in the clinical effects and adverse reactions of ticagrelor. Thromb J, 22(1) : 8.
[33] Xu J,Yan N,Wang C,Gao C,Han X,Yang C,Xu J,Wang K,Mitchell M J,Zhang Y .2023 .Plateletmimicking nanosponges for functional reversal of Antiplatelet agents. Circ. Res., 132(3) : 339-354.
[34] Xu S,Li Y,Zhang Y,Liu A .2024 .Effect of clopidogrel combined with telgrello on the OTC indexes in patients with ST -segment elevation myocardial infarction. Chin Pharm J, 33(15) : 95-98.
[35] Zhen B,Zhang J .2024 .Comparison of the efficacy and safety of Cyp2c19 gene-guided oral administration of different P2Y12 inhibitors in elderly patients with acute coronary syndrome. Acad J Sci Technol., 9(2) : 94-97.
[36] Zhuo M F K L,Shen X B,Lin W C,Hu B,Cai H P and Huang G .2022 .Postoperative adverse cardiac events in acute myocardial infarction with high thrombus load and best time for stent implantation. World J Clin Cases, 10(7) : 2106-2114.